For the quarter ended September 2024, Bausch + Lomb (BLCO) reported revenue of $1.2 billion, up 18.8% over the same period last year. EPS came in at $0.17, compared to $0.22 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $1.17 billion, representing a surprise of +2.54%. The company delivered an EPS surprise of +6.25%, with the consensus EPS estimate being $0.16.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Bausch + Lomb performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Vision Care: $684 million versus $692.53 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +5.6% change.
• Revenue- Surgical: $206 million compared to the $195.68 million average estimate based on three analysts. The reported number represents a change of +11.4% year over year.
• Revenue- Pharmaceuticals: $306 million versus $291.93 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +75.9% change.
• Revenue- Product sales: $1.19 billion versus $1.15 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +18.7% change.
• Revenue- Other: $4 million versus the two-analyst average estimate of $4 million. The reported number represents a year-over-year change of +33.3%.

View all Key Company Metrics for Bausch + Lomb here>>>

Shares of Bausch + Lomb have returned +8.5% over the past month versus the Zacks S&P 500 composite's +1.8% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Bausch + Lomb Corporation (BLCO) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research